New Risk • May 22
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.0m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Market cap is less than US$10m (CA$11.5m market cap, or US$8.31m). Tillkännagivande • May 22
Medicure Inc. to Report Q1, 2026 Results on May 21, 2026 Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026 Reported Earnings • Apr 26
Full year 2025 earnings released: EPS: CA$0.68 (vs CA$0.10 loss in FY 2024) Full year 2025 results: EPS: CA$0.68. Revenue: CA$28.9m (up 32% from FY 2024). Net loss: CA$7.10m (loss widened CA$6.06m from FY 2024). Tillkännagivande • Mar 10
Medicure Inc., Annual General Meeting, May 21, 2026 Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada Reported Earnings • Nov 21
Third quarter 2025 earnings released: CA$0.13 loss per share (vs CA$0.065 profit in 3Q 2024) Third quarter 2025 results: CA$0.13 loss per share (down from CA$0.065 profit in 3Q 2024). Revenue: CA$8.16m (up 58% from 3Q 2024). Net loss: CA$1.40m (down 305% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 14
Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025 Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025 Reported Earnings • Aug 22
Second quarter 2025 earnings released: CA$0.08 loss per share (vs CA$0.12 loss in 2Q 2024) Second quarter 2025 results: CA$0.08 loss per share (improved from CA$0.12 loss in 2Q 2024). Revenue: CA$6.67m (up 29% from 2Q 2024). Net loss: CA$786.0k (loss narrowed 35% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Tillkännagivande • Aug 19
Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025 Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025 Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Director James Kinley was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 26
Full year 2024 earnings released: CA$0.10 loss per share (vs CA$0.088 loss in FY 2023) Full year 2024 results: CA$0.10 loss per share (further deteriorated from CA$0.088 loss in FY 2023). Revenue: CA$21.9m (up 1.0% from FY 2023). Net loss: CA$1.04m (loss widened 13% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Tillkännagivande • Apr 23
Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025 Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025 Tillkännagivande • Mar 12
Medicure Inc., Annual General Meeting, May 21, 2025 Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada Reported Earnings • Nov 26
Third quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 3Q 2023) Third quarter 2024 results: EPS: CA$0.07 (up from CA$0.008 in 3Q 2023). Revenue: CA$5.15m (up 3.0% from 3Q 2023). Net income: CA$680.0k (up CA$596.0k from 3Q 2023). Profit margin: 13% (up from 1.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year. Tillkännagivande • Nov 22
Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors Medicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024. Tillkännagivande • Nov 19
Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024 Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023) Second quarter 2024 results: CA$0.12 loss per share (down from CA$0.024 profit in 2Q 2023). Revenue: CA$5.17m (down 14% from 2Q 2023). Net loss: CA$1.22m (down CA$1.47m from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 17
Now 35% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.9% to CA$1.00. The fair value is estimated to be CA$1.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • May 30
Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director Medicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board. Reported Earnings • May 29
First quarter 2024 earnings released First quarter 2024 results: Revenue: CA$5.69m (up 1.2% from 1Q 2023). Net income: CA$51.0k (down 82% from 1Q 2023). Profit margin: 0.9% (down from 5.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • May 14
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to CA$1.06. The fair value is estimated to be CA$1.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Apr 21
Medicure Inc., Annual General Meeting, May 28, 2024 Medicure Inc., Annual General Meeting, May 28, 2024. Reported Earnings • Apr 12
Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022) Full year 2023 results: CA$0.088 loss per share (down from CA$0.13 profit in FY 2022). Revenue: CA$21.7m (down 5.9% from FY 2022). Net loss: CA$922.0k (down 168% from profit in FY 2022). Products in clinical trials Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 05
Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024 Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024 New Risk • Jan 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$12.0m market cap, or US$8.90m). Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin). New Risk • Jan 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$11.1m (US$8.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$11.1m market cap, or US$8.24m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin). Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to CA$1.06, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Biotechs industry in North America. Total loss to shareholders of 23% over the past three years. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CA$1.32, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 55% over the past three years. Tillkännagivande • Nov 24
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease Medicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application. Reported Earnings • Nov 24
Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022) Third quarter 2023 results: EPS: CA$0.01 (down from CA$0.11 in 3Q 2022). Revenue: CA$5.00m (down 5.4% from 3Q 2022). Net income: CA$84.0k (down 93% from 3Q 2022). Profit margin: 1.7% (down from 21% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. New Risk • Nov 23
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (CA$15.7m market cap, or US$11.4m). New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$14.8m market cap, or US$10.7m). Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CA$1.50, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 15x in the Biotechs industry in North America. Total returns to shareholders of 88% over the past three years. Reported Earnings • Jul 30
Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022) Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.067 loss in 2Q 2022). Revenue: CA$5.99m (up 4.3% from 2Q 2022). Net income: CA$253.0k (up CA$936.0k from 2Q 2022). Profit margin: 4.2% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 25
Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023 Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023 New Risk • Jul 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$13.5m market cap, or US$10.2m). Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CA$1.13, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 13x in the Biotechs industry in North America. Total returns to shareholders of 5.6% over the past three years. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CA$1.35, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 12x in the Biotechs industry in North America. Total returns to shareholders of 36% over the past three years. Reported Earnings • May 28
First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022) First quarter 2023 results: EPS: CA$0.03 (down from CA$0.047 in 1Q 2022). Revenue: CA$5.63m (down 1.5% from 1Q 2022). Net income: CA$290.0k (down 40% from 1Q 2022). Profit margin: 5.2% (down from 8.4% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 05
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CA$1.01, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CA$1.39, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 17% over the past three years. Reported Earnings • Apr 08
Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021) Full year 2022 results: EPS: CA$0.13 (up from CA$0.071 loss in FY 2021). Revenue: CA$23.1m (up 6.1% from FY 2021). Net income: CA$1.37m (up CA$2.09m from FY 2021). Profit margin: 5.9% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 02
Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors Medicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004. Valuation Update With 7 Day Price Move • Jan 17
Investor sentiment improved over the past week After last week's 18% share price gain to CA$1.25, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 64% over the past three years. Recent Insider Transactions • Dec 23
Founder recently bought CA$67k worth of stock On the 16th of December, Albert Friesen bought around 67k shares on-market at roughly CA$1.00 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Albert has been a buyer over the last 12 months, purchasing a net total of CA$184k worth in shares. Reported Earnings • Nov 25
Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021) Third quarter 2022 results: EPS: CA$0.11 (up from CA$0.092 loss in 3Q 2021). Revenue: CA$5.29m (up 7.5% from 3Q 2021). Net income: CA$1.11m (up CA$2.06m from 3Q 2021). Profit margin: 21% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 18
Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022 Medicure Inc. announced that they will report Q3, 2022 results on Nov 25, 2022 Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 25
Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021) Second quarter 2022 results: CA$0.067 loss per share (down from CA$0.062 loss in 2Q 2021). Revenue: CA$5.75m (up 13% from 2Q 2021). Net loss: CA$683.0k (loss widened 6.9% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improved over the past week After last week's 44% share price gain to CA$1.37, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 70% over the past three years. Tillkännagivande • Aug 18
Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022 Medicure Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022 Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment improved over the past week After last week's 29% share price gain to CA$1.16, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 77% over the past three years. Tillkännagivande • Jun 21
Medicure Inc. Appoints James Kinley as Director Medicure Inc. announced that James Kinley was elected as director at its Annual General Meeting of shareholders held on June 16, 2022. Reported Earnings • Jun 01
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: EPS: CA$0.047 (up from CA$0.10 loss in 1Q 2021). Revenue: CA$5.72m (up 16% from 1Q 2021). Net income: CA$482.0k (up CA$1.53m from 1Q 2021). Profit margin: 8.4% (up from net loss in 1Q 2021). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Tillkännagivande • May 31
Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022 Medicure Inc. announced the appointment of Mr. Haaris Uddin (CPA, B.Comm.) as Chief Financial Officer, effective June 1, 2022. Mr. Uddin as Chief Financial Officer, he began his career with Ernst & Young LLP as a senior accountant in assurance services and brings experience in public company reporting within the life sciences industry in both Canada and the United States. Reported Earnings • Apr 29
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: CA$0.07 loss per share (up from CA$0.64 loss in FY 2020). Revenue: CA$21.7m (up 87% from FY 2020). Net loss: CA$727.0k (loss narrowed 89% from FY 2020). Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 16
Medicure Inc., Annual General Meeting, Jun 16, 2022 Medicure Inc., Annual General Meeting, Jun 16, 2022. Tillkännagivande • Nov 24
Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of Americans Medicure Inc. announced that it is planning to launch a national direct-to-consumer E-Commerce pharmacy platform through its subsidiary, Marley Drug™ pharmacy, before the end of 2021. Marley Drug's new E-Commerce website will be a platform where FDA approved medications can be purchased at discount prices by Americans for home delivery in all 50 States, including ZYPITAMAG® (pitavastatin) tablets. A primary goal of the platform is to bypass the traditional framework run by health insurers and pharmacy benefit managers that have made access to affordable medications challenging for many Americans, including both generic and branded products such as ZYPITAMAG. More than 120 million uninsured and underinsured Americans struggle to access affordable medications and are looking for a trusted and convenient source to fill their prescriptions. Marley Drug will offer industry leading pricing on more than 100 of the most commonly prescribed generic medications with free nationwide delivery. The platform will focus on ease-of-use and customer service, and is differentiated by being able to ship to every US state. Notably, the pharmacy platform addresses 'pharmacy deserts' that exist across the country. A 'pharmacy desert' is defined as a geographic area where Americans can't fill a prescription within a half-a-mile of their homes (for low-income people without cars), and a mile for others. This lack of quick access to a pharmacy affects many Americans. Reported Earnings • Nov 24
Third quarter 2021 earnings: EPS and revenues miss analyst expectations Third quarter 2021 results: CA$0.09 loss per share (up from CA$0.098 loss in 3Q 2020). Revenue: CA$4.92m (up 39% from 3Q 2020). Net loss: CA$946.0k (loss narrowed 9.6% from 3Q 2020). Revenue missed analyst estimates by 46%. Earnings per share (EPS) also missed analyst estimates by 100%. Earnings per share (EPS) missed analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 28
Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$5.09m (up 90% from 2Q 2020). Net loss: CA$639.0k (down CA$658.0k from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 33 percentage points per year, which is a significant difference in performance. Executive Departure • May 18
CFO & Secretary has left the company On the 15th of May, James Kinley's tenure in the role of CFO & Secretary ended. As of December 2020, James personally held only 47.10k shares (CA$56k worth at the time). James is the only executive to leave the company over the last 12 months. Reported Earnings • May 12
First quarter 2021 earnings released The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$4.94m (up 64% from 1Q 2020). Net loss: CA$1.05m (loss narrowed 28% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 24
Full year 2020 earnings released The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$11.6m (down 42% from FY 2019). Net loss: CA$6.85m (loss narrowed 65% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 23
New 90-day high: CA$1.70 The company is up 127% from its price of CA$0.75 on 24 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Tillkännagivande • Jan 28
Medicure Announces Early Completion of Enrollment for iSPASM Medicure Inc. announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI assessed by the rates of symptomatic and asymptomatic bleeding. iSPASM was funded by an unrestricted educational grant from Medicure. This study does not imply efficacy of AGGRASTAT® in patients with aSAH. Please note that the use of AGGRASTAT® in neurointerventions has not been approved by the FDA. As of this time, neither AGGRASTAT® nor any of the GP IIb/IIIa inhibitors are indicated for the use in stroke patients. AGGRASTAT® is approved for use in NSTE-ACS patients. Refer to Important Safety Information below and the U.S. Prescribing Information for complete product information. Is New 90 Day High Low • Jan 23
New 90-day high: CA$1.65 The company is up 81% from its price of CA$0.91 on 22 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: CA$1.23 The company is up 37% from its price of CA$0.90 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 17
New 90-day high: CA$1.15 The company is up 20% from its price of CA$0.96 on 18 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 16% over the same period. Is New 90 Day High Low • Nov 19
New 90-day low: CA$0.75 The company is down 32% from its price of CA$1.10 on 14 August 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period. Tillkännagivande • Nov 06
Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020 Medicure Inc. announced that they will report Q3, 2020 results at 10:00 PM, GMT Standard Time on Nov 11, 2020 Is New 90 Day High Low • Oct 31
New 90-day low: CA$0.80 The company is down 25% from its price of CA$1.06 on 31 July 2020. The Canadian market is down 26% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 11% over the same period. Is New 90 Day High Low • Sep 23
New 90-day low: CA$0.93 The company is down 7.0% from its price of CA$1.00 on 25 June 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period. Tillkännagivande • Aug 06
Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020 Medicure Inc. announced that they will report Q2, 2020 results on Aug 11, 2020 Tillkännagivande • Jul 20
Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index